Multi-million-dollar investments by Anges will help Vasomune progress its peptide-based therapy for blood vessel-related diseases to the clinic.
Vasomune Theraueptics, a Canada-based critical care peptide spinout from Sunnybrook Research Institute (SRI) and commercialisation firm Mars Innovation, has secured multi-million-dollar commitments from biotherapeutics manufacturer Anges.
The commitments are part of a co-development partnership between the pair focused on treating blood vessel-related diseases with Vasomune’s peptide-based Tie2 receptor agonist, branded Vasculotide.
Anges will provide Vasomune with upfront and clinical milestone payments. Both parties will equally share all expenses and proceeds, including those resulting from any third-party licensing agreement.
The partners…
